Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Senate throws FDA user fees into disarray

Senate throws FDA user fees into disarray

WASHINGTON - The fate of FDA user fees for Fiscal 1994 will be determined by a House-Senate conference committee that is reconciling differences in

Read the full 317 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE